HK1044887A1 - Use of tumor necrosis factor alpha (tnf-alpha) and vascular endothelial growth factor (vegf) for the manufacture of a therapeutic composition - Google Patents

Use of tumor necrosis factor alpha (tnf-alpha) and vascular endothelial growth factor (vegf) for the manufacture of a therapeutic composition Download PDF

Info

Publication number
HK1044887A1
HK1044887A1 HK02105101.3A HK02105101A HK1044887A1 HK 1044887 A1 HK1044887 A1 HK 1044887A1 HK 02105101 A HK02105101 A HK 02105101A HK 1044887 A1 HK1044887 A1 HK 1044887A1
Authority
HK
Hong Kong
Prior art keywords
tumor necrosis
vegf
antagonist
necrosis factor
tnfα
Prior art date
Application number
HK02105101.3A
Other languages
English (en)
Chinese (zh)
Inventor
Feldmann Marc
Nath Maini Ravinder
Maria Paleolog Ewa
Original Assignee
The Kennedy Institute Of Rheumatology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Kennedy Institute Of Rheumatology filed Critical The Kennedy Institute Of Rheumatology
Publication of HK1044887A1 publication Critical patent/HK1044887A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK02105101.3A 1997-05-12 2002-07-09 Use of tumor necrosis factor alpha (tnf-alpha) and vascular endothelial growth factor (vegf) for the manufacture of a therapeutic composition HK1044887A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US854881 1992-03-20
US85488197A 1997-05-12 1997-05-12

Publications (1)

Publication Number Publication Date
HK1044887A1 true HK1044887A1 (en) 2002-11-08

Family

ID=25319772

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02105101.3A HK1044887A1 (en) 1997-05-12 2002-07-09 Use of tumor necrosis factor alpha (tnf-alpha) and vascular endothelial growth factor (vegf) for the manufacture of a therapeutic composition

Country Status (6)

Country Link
EP (2) EP0980258A1 (enExample)
JP (1) JP2001525816A (enExample)
AU (1) AU7345798A (enExample)
CA (1) CA2290021A1 (enExample)
HK (1) HK1044887A1 (enExample)
WO (1) WO1998051344A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
EP1049773B1 (en) 1998-01-22 2007-07-25 Btg International Limited Inhibition of cytokine production
JP2002538170A (ja) * 1999-03-02 2002-11-12 セントコール， インコーポレイテッド 喘息の治療における抗−ＴＮＦα抗体
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7662367B2 (en) 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
AU4541101A (en) * 2000-03-02 2001-09-12 Xencor Inc Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
MXPA05003889A (es) 2002-10-15 2005-06-22 Celgene Corp Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
JP2007504122A (ja) 2003-08-29 2007-03-01 ファイザー・インク 新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体
WO2005041877A2 (en) * 2003-10-29 2005-05-12 Children's Medical Center Corporation Method of inhibiting rejection following organ transplantation
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
BRPI0610058A2 (pt) 2005-05-16 2010-05-25 Abbott Biotech Ltd uso de inibidor de tnf para tratamento da poliartrite erosiva
JP2008120722A (ja) * 2006-11-10 2008-05-29 Benesis Corp 生物由来製品の偽薬
EP2408493B1 (en) 2009-03-20 2024-07-24 Antares Pharma, Inc. Hazardous agent injection system
CA2832759A1 (en) 2011-05-06 2012-11-15 Bio-Rad Laboratories, Inc. Thermal cycler with vapor chamber for rapid temperature changes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233701T2 (de) * 1991-03-18 2008-04-10 New York University Monoklonale und chimäre Antikörper spezifisch für menschlichen Tumornekrosefaktor
JPH07504203A (ja) * 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP1238986B1 (en) * 1992-10-28 2008-06-25 Genentech, Inc. Use of Vascular endothelial cell growth factor antagonists
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists

Also Published As

Publication number Publication date
AU7345798A (en) 1998-12-08
WO1998051344A1 (en) 1998-11-19
EP0980258A1 (en) 2000-02-23
EP1170017A1 (en) 2002-01-09
JP2001525816A (ja) 2001-12-11
CA2290021A1 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
EP1170017A1 (en) Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition
EP0936923B1 (en) SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
CN111068062B (zh) 治疗白介素-6相关疾病的方法
ES2247635T3 (es) Anticuerpos anti-tnf/receptor de tnf y metotrexato en el tratamiento de enfermedades autoinmunes.
EP0783893B1 (en) Inhibition of abnormal growth of synovial cells using il-6 antagonist as active ingredient
US5888510A (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US8017121B2 (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
WO2001037874A2 (en) Treatment of psoriasis by using an antibody to tnf alpha
US6770279B1 (en) TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
AU2003264629B2 (en) Anti-TNF Antibodies and Methotrexate in the Treatment of Autoimmune Disease
AU2012202134B2 (en) Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
HK40019620A (en) Methods for treating interleukin-6 related diseases
HK40019620B (en) Methods for treating interleukin-6 related diseases
AU2013202407B2 (en) Anti-TNF antibodies and methotrexate in the treatment of autoimmune disease
AU732764B2 (en) Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
HK1096859B (en) Methods for treating interleukin-6 related diseases
HK1158078A (en) Methods for treating interleukin-6 related diseases
HK1020011B (en) Anti-tnf antibodies and methotrexate in the treatment of autoimmune disease